The latest price target for Abbott Laboratories (NYSE:ABT) was reported by Barclays on February 2, 2026. The analyst firm set a price target for $142.00 expecting ABT to rise to within 12 months (a possible 26.05% upside). 45 analyst firms have reported ratings in the last year.

The latest analyst rating for Abbott Laboratories (NYSE:ABT) was provided by Barclays, and Abbott Laboratories maintained their overweight rating.

The last upgrade for Abbott Laboratories happened on July 18, 2025 when Jefferies raised their price target to $145. Jefferies previously had a hold for Abbott Laboratories.

There is no last downgrade for Abbott Laboratories.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Abbott Laboratories, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Abbott Laboratories was filed on February 2, 2026 so you should expect the next rating to be made available sometime around February 2, 2027.

While ratings are subjective and will change, the latest Abbott Laboratories (ABT) rating was a maintained with a price target of $169.00 to $142.00. The current price Abbott Laboratories (ABT) is trading at is $112.65, which is out of the analyst’s predicted range.